程立婷, 李翀. 靶向动脉粥样硬化病灶的细胞膜仿生递药系统的初步研究J. 药学学报, 2018,53(2): 297-303. doi: 10.16438/j.0513-4870.2017-0999
引用本文: 程立婷, 李翀. 靶向动脉粥样硬化病灶的细胞膜仿生递药系统的初步研究J. 药学学报, 2018,53(2): 297-303. doi: 10.16438/j.0513-4870.2017-0999
CHENG Li-ting, LI Chong. A preliminary study on the biomimetic drug delivery system targeting atherosclerotic lesionsJ. Acta Pharmaceutica Sinica, 2018,53(2): 297-303. doi: 10.16438/j.0513-4870.2017-0999
Citation: CHENG Li-ting, LI Chong. A preliminary study on the biomimetic drug delivery system targeting atherosclerotic lesionsJ. Acta Pharmaceutica Sinica, 2018,53(2): 297-303. doi: 10.16438/j.0513-4870.2017-0999

靶向动脉粥样硬化病灶的细胞膜仿生递药系统的初步研究

A preliminary study on the biomimetic drug delivery system targeting atherosclerotic lesions

  • 摘要: 基于巨噬细胞与动脉粥样硬化病灶之间的天然亲和性,本文拟构建一种新型的巨噬细胞膜包裹聚乳酸-羟基乙酸共聚物(PLGA)纳米粒(macrophage-membrane-coated PLGA nanoparticles,MPLNPs)仿生递药系统,并对其靶向动脉粥样硬化病灶的功能进行初步评价。采用沉淀法制备PLGA纳米粒(PLGANPs)及纳米膜挤压法制备MPLNPs,对其形态、粒径及携带功能蛋白进行表征;进一步通过体外细胞模型摄取和动物模型体内荧光成像考察其靶向性。结果表明,MPLNPs呈球形,具有明显的核/壳结构,平均粒径为(167 ±6.12) nm,表面保留了整合素α4β1(integrin α4β1,α4β1);用脂多糖(LPS)诱导建立的人脐静脉内皮细胞(HUVEC)损伤模型及用ApoE-/-(载脂蛋白E敲除)小鼠建立的动脉粥样硬化模型血管损伤处均高表达血管细胞黏附分子-1(VCAM-1)受体,制备的MPLNPs能有效识别VCAM-1受体并呈现出良好的体内外靶向性。本研究探索制备的细胞膜仿生纳米载体,有望为动脉粥样硬化及相关疾病治疗提供新思路。

     

    Abstract: Based on the natural affinity between macrophages and atherosclerotic lesions, we made a novel macrophage membrane-coated polylactic acid-glycolic acid copolymer (PLGA) nanoparticle (MPLNPs), and examined its ability targeting atherosclerotic lesions. PLGA nanoparticle (PLGANPs) were prepared by precipitation and MPLNPs were prepared by membrane extrusion. Their morphology, particle size and retainment of functional proteins were characterized. Their targeting capabilities were investigated with cell uptake assay in vitro and fluorescence imaging in vivo. The results showed that MPLNPs were spherical, with obvious core/shell structure, the average particle size was (167 ±6.12) nm, and integrin α4β1 was retained on the surface. Vascular cell adhesion molecule 1 (VCAM-1) receptor was highly expressed in the LPS (lipopolysaccharides)-HUVEC (human umbilical vein endothelial cells) and atherosclerotic lesions in ApoE-/- mouse model, and the nanoparticles could effectively recognize the VCAM-1 receptor and had good targeting properties in vitro and in vivo. The results suggest that the cell membrane biomimetic nano-carrier may provide a new approach for the targeting strategy in the treatment of atherosclerosis and related diseases.

     

/

返回文章
返回